Sinopharm Group (01099) Announces January 2026 Monthly Return with No Change in Share Movements

Bulletin Express

02/05

Sinopharm Group Co. Ltd. (Stock Code: 01099) submitted a Monthly Return for the period ended 31 January 2026, confirming no changes to its share capital. The total authorized/registered share capital of RMB 3,120,656,191 remains divided into 1,341,810,740 H shares and 1,778,845,451 domestic shares, each with a par value of RMB 1. The document also notes that, as the company is incorporated in the People’s Republic of China, the concept of authorized share capital is not directly applicable.

All issued H shares stood at 1,341,810,740 shares with no shares held in treasury. For domestic shares, the figure remained 1,778,845,451. The firm confirmed compliance with the applicable public float requirement, specified at an initial 25 percent threshold for this category. The submission, dated 5 February 2026, stated that there were no share option arrangements, warrants, or convertible securities in issue during the period.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1157938285"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157938285\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157938285?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 06:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157938285","market":"us","top_or_hot":-1,"title":"Sinopharm Group (01099) Announces January 2026 Monthly Return with No Change in Share Movements","media":"Bulletin Express","content":"<p>Sinopharm Group Co. Ltd. (Stock Code: 01099) submitted a Monthly Return for the period ended 31 January 2026, confirming no changes to its share capital. The total authorized/registered share capital of RMB 3,120,656,191 remains divided into 1,341,810,740 H shares and 1,778,845,451 domestic shares, each with a par value of RMB 1. The document also notes that, as the company is incorporated in the People’s Republic of China, the concept of authorized share capital is not directly applicable.</p>\n<p>All issued H shares stood at 1,341,810,740 shares with no shares held in treasury. For domestic shares, the figure remained 1,778,845,451. The firm confirmed compliance with the applicable public float requirement, specified at an initial 25 percent threshold for this category. The submission, dated 5 February 2026, stated that there were no share option arrangements, warrants, or convertible securities in issue during the period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Group (01099) Announces January 2026 Monthly Return with No Change in Share Movements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Group (01099) Announces January 2026 Monthly Return with No Change in Share Movements\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-02-05 06:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sinopharm Group Co. Ltd. (Stock Code: 01099) submitted a Monthly Return for the period ended 31 January 2026, confirming no changes to its share capital. The total authorized/registered share capital of RMB 3,120,656,191 remains divided into 1,341,810,740 H shares and 1,778,845,451 domestic shares, each with a par value of RMB 1. The document also notes that, as the company is incorporated in the People’s Republic of China, the concept of authorized share capital is not directly applicable.</p>\n<p>All issued H shares stood at 1,341,810,740 shares with no shares held in treasury. For domestic shares, the figure remained 1,778,845,451. The firm confirmed compliance with the applicable public float requirement, specified at an initial 25 percent threshold for this category. The submission, dated 5 February 2026, stated that there were no share option arrangements, warrants, or convertible securities in issue during the period.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"國藥控股","start_time":0,"source_url":"","article_id":"1157938285","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157938285","pubTimestamp":1770245075,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinopharm Group Co. Ltd. (Stock Code: 01099) submitted a Monthly Return for the period ended 31 January 2026, confirming no changes to its share capital. The total authorized/registered share capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药集团(01099)公布2026年1月股份变动月报表无变动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Group Co. Ltd. (Stock Code: 01099) submitted a Monthly Return for the period ended 31 January 2026, confirming no changes to its share capital. The total authorized/registered share capital of RMB 3,120,656,191 remains divided into 1,341,810,740 H shares and 1,778,845,451 domestic shares, each with a par value of RMB 1. The document also notes that, as the company is incorporated in the People’s Republic of China, the concept of authorized share capital is not directly applicable.\nAll issued H shares stood at 1,341,810,740 shares with no shares held in treasury. For domestic shares, the figure remained 1,778,845,451. The firm confirmed compliance with the applicable public float requirement, specified at an initial 25 percent threshold for this category. The submission, dated 5 February 2026, stated that there were no share option arrangements, warrants, or convertible securities in issue during the period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}